MUC1 based glycolipopeptide vaccine with adjuvant
US8889616B2 · kind B2 · utility
11Cited by
32References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 23, 2012 |
| Grant date | Nov 18, 2014 |
| Priority date | — |
| Expiry date | Apr 20, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/585
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are liposomal glycolipopeptidic vaccine formulations comprising an adjuvant and an immunogen for immunotherapy and/or treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.